According to the company, Megan Baldwin, PhD, CEO of Opthea Ltd, will provide an overview of the company’s Phase 3 clinical program advancing OPT-302 for the treatment of wet AMD.
Megan Baldwin, PhD, CEO of Opthea Ltd, will provide an overview of the company’s Phase 3 clinical program advancing OPT-302 for the treatment of wet AMD at the 2023 Opthalmology Innovation Summit being held Thursday in Seattle, Washington.
According to the company, Baldwin’s presentation is part of the Innovation Showcase session taking place from 8:35 am to 10 am PT.
Opthea’s lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone.
Founded in 2009, the OIS brings together entrepreneurs, clinical thought leaders, industry executives, start-up companies, and investment professionals in a single forum to showcase and discuss novel therapies targeting unmet clinical needs.
Over the past decade, the OIS has grown into the Ophthalmology Innovation Source, offering an extensive range of media, events, and data that provide crucial insights and enable significant connections.
A copy of the presentation will be made available on Opthea’s website.
Opthea is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).